Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : REFILE-UPDATE 3-Emergent to resume J&J COVID-19 vaccine production at Baltimore plant

07/29/2021 | 12:25am EDT

July 29 (Reuters) - Emergent BioSolutions said on Wednesday it will resume production of Johnson & Johnson's COVID-19 vaccine at its troubled Baltimore facility, where operations were stopped in April after millions of doses were found to be contaminated.

The development comes after J&J last week slashed 2021 production target of its single-dose vaccine to between 500 million and 600 million doses from its original goal to produce a billion shots.

The resumption follows additional reviews and collaboration with the FDA and manufacturing partners, Emergent Chief Executive Officer Robert Kramer said.

The FDA has so far approved five batches from the Emergent facility since production there was paused, and J&J is working to clear additional doses for use, the drugmaker said last week.

U.S. health regulators in April halted operations at the Baltimore plant following a discovery that ingredients from AstraZeneca's COVID-19 vaccine, also being produced there at that time, contaminated a batch of J&J's vaccines.

An FDA inspection also turned up a long list of sanitary problems and bad manufacturing practices.

J&J's vaccine, considered more convenient for use, storing and shipping to remote areas, has seen a relatively slow uptake in Europe and the United States due to safety concerns and the production issues.

"We will continue to work toward securing Emergency Use Authorization in the United States for drug substance manufactured at Emergent Bayview as quickly as possible," J&J said in an email.

The FDA did not immediately respond to a Reuters request for comment.

The Wall Street Journal, which first reported the news, cited a letter from the FDA saying the agency had no objections with the plant resuming manufacturing. (https://on.wsj.com/3iXSAfg)

The facility could make as many as 120 million doses a month at full capacity, but the finished doses might not be available until this fall, the Journal reported. (Reporting by Aishwarya Nair, Maria Ponnezhath and Manojna Maddipatla in Bengaluru; Editing by Subhranshu Sahu, Ramakrishnan M. and Shounak Dasgupta)


© Reuters 2021
All news about ASTRAZENECA PLC
07:42aASTRAZENECA : Enhertu demonstrated robust and durable tumour response of 54.9% i..
PU
07:31aASTRAZENECA : ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated robust and..
BU
09/17The case for, and against, COVID-19 vaccine boosters
RE
09/17ASTRAZENECA : Enhertu demonstrated clinically meaningful and durable response in..
PU
09/17ASTRAZENECA : ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically..
BU
09/17AstraZeneca Sees Positive Results for Enhertu Trial
DJ
09/17ASTRAZENECA : EMA Fails To Find Link Between Blood Clots, AstraZeneca's Vaccine
MT
09/17ASTRAZENECA : Says Imfinzi-Oleclumab Combination Improved Clinical Outcomes for ..
MT
09/17JOHNSON & JOHNSON : GSA Director Lauded for Luring More People to Get Covid-19 V..
AQ
09/17ASTRAZENECA : EU unsure if women face higher risk of clots from AstraZeneca shot
RE
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 214 M - -
Net income 2021 4 990 M - -
Net Debt 2021 24 654 M - -
P/E ratio 2021 31,1x
Yield 2021 2,54%
Capitalization 172 B 172 B -
EV / Sales 2021 5,57x
EV / Sales 2022 4,50x
Nbr of Employees 76 100
Free-Float 96,3%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 110,77 $
Average target price 136,08 $
Spread / Average Target 22,9%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC10.09%171 794
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.20.81%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY36.28%208 604